Free Newsletter
Experimental vax targets aggressive tumors
A new vaccine that targets HER2-positive tumor cells was successful in eliminating tumors in laboratory animals. And researchers say that the vaccine may well stop cancer from reoccurring in women or be used as an advance therapy for drug-resistant forms of breast cancer. HER2-positive tumor cells are responsible for one of the most aggressive forms of cancer. The vaccine contains a gene that spurs the development of HER2 receptors, triggering an immune system response directed against them.
Dr. Minetta Liu, director of translational breast cancer research at Lombardi Comprehensive Cancer Center at Georgetown University, says that the research indicates that the vaccine may restore drug sensitivity to tumor cells. "It's valuable research, potentially groundbreaking."
Dr. Wei-Zen Wei, a professor of immunology and microbiology at the Karmanos Cancer Center at Wayne State University, led the study, which was published in Cancer Research.
- read the story from the Washington Post
Related Articles:
Invitrogen gets breast cancer test approval
EMEA issues host of decisions
Pertuzumab slows breast cancer in study
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




